memberNew report calls Canada’s alternative protein industry ‘hotbed of innovation and key country to do business in’
Game Changers is the first report to compile Canada’s extensive activity in alternative protein development in one place.
Members
Immunofyx
ImmunoFyx is a private early-stage biotechnology company focused on novel antibody fusion proteins targeting highly metastatic solid tumours. Up to 90% of cancer deaths are associated with metastases for which there are few treatment options. ImmunoFyx utilizes unique combinations of endogenous anti-cancer proteins to reduce tumour growth, angiogenesis and metastases.